Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standardized grass pollen is a **non-specific allergen immunotherapy product descriptor**, not a single uniquely identifiable drug. In the cited literature it refers to standardized extracts of grass pollen allergens, including five-grass pollen preparations used for **allergen-specific immunotherapy** in seasonal allergic rhinitis or rhinoconjunctivitis. These products are administered by the sublingual or subcutaneous route to induce immune tolerance to grass pollen allergens, with reported effects including reduced symptoms and rescue-medication use, increases in allergen-specific IgG and IgG4, and modulation of type 2 immune responses. However, the exact composition, manufacturer, and commercial product vary across studies, so the term should be treated as a broad allergen-extract concept rather than a single pharmaceutical asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standardized grass pollen.